VOYDEYA Drug Patent Profile

✉ Email this page to a colleague

When do Voydeya patents expire, and what generic alternatives are available?

Voydeya is a drug marketed by Alexion Pharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and seven patent family members in twenty-four countries.

The generic ingredient in VOYDEYA is danicopan. One supplier is listed for this compound. Additional details are available on the danicopan profile page.

DrugPatentWatch^® Generic Entry Outlook for Voydeya

Voydeya will be eligible for patent challenges on March 29, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for VOYDEYA?
What are the global sales for VOYDEYA?
What is Average Wholesale Price for VOYDEYA?

Summary for VOYDEYA

International Patents:	107
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	31
What excipients (inactive ingredients) are in VOYDEYA?	VOYDEYA excipients list
DailyMed Link:	VOYDEYA at DailyMed

Drug patent expirations by year for VOYDEYA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VOYDEYA

Generic Entry Date for VOYDEYA^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NDA: 218037 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VOYDEYA

VOYDEYA is protected by two US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOYDEYA is ⤷ Sign Up.

This potential generic entry date is based on TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VOYDEYA

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB

Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB

FDA Regulatory Exclusivity protecting VOYDEYA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for VOYDEYA

See the table below for patents covering VOYDEYA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Korea	20160119241	보체 매개 질환의 치료를 위한 화합물 (COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS)	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2015130795		⤷ Sign Up
Canada	2940769	COMPOSES AMINES POUR TRAITER LES TROUBLES A MEDIATION PAR LE COMPLEMENT (AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS)	⤷ Sign Up
Israel	247452	תרכובות לטיפול בהפרעות מתווכות משלימות (Compounds for treatment of complement mediated disorders)	⤷ Sign Up
Canada	2940777	COMPOSES POUR TRAITER LES TROUBLES A MEDIATION PAR LE COMPLEMENT (COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS)	⤷ Sign Up
Japan	2017508788	補体媒介障害の治療のためのエーテル化合物	⤷ Sign Up
Russian Federation	2016137677	АРИЛЬНЫЕ, ГЕТЕРОАРИЛЬНЫЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ КОМПЛЕМЕНТОМ РАССТРОЙСТВ	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration